Fig. 1 · Structure

Documents & Downloads

Tenofovir Disoproxil Fumarate

Cat. No. A10909 CAS 202138-50-9

nucleotide reverse transcriptase inhibitor

Tenofovir Disoproxil Fumarate is employed as an anti-HIV agend and a reverse transcriptase inhibitor.

In Stock

Publications for Tenofovir Disoproxil Fumarate

2 publications citing this product

  1. Ryogo Shimizu, .et al. , Hepatol Commun, 2024, Jan 5;8(1):e0351 PMID: 38180972
  2. Kazumoto Murata, .et al. , Gut, 2018, Feb; 67(2): 362-371 PMID: 27789659

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Tenofovir disoproxil fumarate (TDF) delivers tenofovir-derived metabolites intracellularly. In VK2 cells, TDF exposure generated tenofovir monophosphate and tenofovir diphosphate (TFV-DP). [1]

Cellular retention of TDF-derived material is influenced by esterases. BNPP pretreatment reduced radiolabeled TDF accumulation in VK2 cells and PBMCs, while TFV accumulation was not significantly affected. Radioactivity includes parent drug and metabolites; it does not measure intact TDF alone. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
HIV reverse transcriptase (Cell-free assay)

Cellular Effect

Cell Line Activity Value Description Reference
Bone marrow cell CC50 0.9 μM Cytotoxicity against human bone marrow cells after 24 hrs by BFU-E assay [PMID: 20439609]
Bone marrow cell CC50 1.9 μM Cytotoxicity against human bone marrow cells after 24 hrs by GM-CFU assay [PMID: 20439609]
HepG2 IC50 2.31 μM Cytotoxicity against human HepG2 cells after 9 days by MTT assay [PMID: 17888662]
HepG2 IC50 5.1 μM Antiviral activity against Hepatitis B virus infected human HepG2 cells after 9 days by MTT assay [PMID: 17888662]
HepG2 CC50 64.5 μM Cytotoxicity in uninfected human hepG2 assessed as reduction in cell viability by XTT assay [PMID: 27933889]
HepG2 2.2.15 CC50 29.2 μM Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability after 6 days by XTT assay [PMID: 27405794]
MT2 EC50 0.015 μM Inhibition of virus-induced cytopathic effect in wild type HIV 3a infected MT2 cells after 5 days [PMID: 17562366]
MT2 EC50 6.8 nM Antiviral activity against HIV1 3B infected in human MT-2 cells by two fold dilution method in presence of 10% FBS [PMID: 19104010]
MT4 CC50 > 20 μM Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 6 days by XTT tetrazolium dye-based assay [PMID: 28682067]
PBMC CC50 14.56 μM Cytotoxicity against human PHA-stimulated PBMC assessed as cell viability by tetrazolium dye assay [PMID: 28682067]
PBMC CC50 43.7 μM Cytotoxicity against human PBMC assessed as reduction in cell viability by XTT assay [PMID: 27405794]
PBMC CC50 44 μM Cytotoxicity in uninfected human PBMC assessed as reduction in cell viability by XTT assay [PMID: 27933889]

12 records · Scroll to view more

Tenofovir Disoproxil Fumarate Research Summary

This section summarizes 4 in vitro studies and 2 in vivo studies of Tenofovir Disoproxil Fumarate from 5 published references. In vitro models include human vaginal epithelial VK2 cells; VK2 cells and human PBMCs.

Tenofovir Disoproxil Fumarate In Vitro Studies

TDF induced IFN-λ3 secretion in WiDr and HT-29 colon cancer cells after 48 hours, with a dose-dependent response. The tested non-colon cell panel did not show induction by the nucleos(t)ide analogues despite responsiveness to positive controls. This response is cell-type-dependent. [2]

In serum-starved HepG2 cells, 50 μM TDF pretreatment for 24 hours reduced insulin-stimulated INSRβ phosphorylation and downstream signaling relative to untreated and entecavir-treated conditions. These host-cell observations do not establish clinical cancer prevention or a receptor inhibition constant. [3]

Cellular formation of tenofovir diphosphate from TDF

Cell-based study · Human vaginal epithelial VK2 cells [1]

TDF exposure generated mono-protected TFV, TFV, TFV-MP and TFV-DP. Intracellular TFV and phosphorylated products were similar at 90 and 450 μM TDF; metabolite formation was nonlinear.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Formation of TFV-MP and TFV-DP after TDF exposureQualitative metabolite kinetics TFV and phosphorylated metabolite levels did not differ between the two TDF concentrations[1]

Literature-Reported Treatment Conditions

Treatment concentration
TDF: 90 and 450 μM; separate TFV comparator: 450 and 1,350 μM
Exposure duration
15 min to 12 h
Method
HPLC-MS/MS of cell-associated parent drug and metabolites; serum-free RPMI 1640 at 37°C
Co-treatment
None; TFV was a separate comparator
Reported limits
Vehicle is not specified in Figure 6/caption. At 90 μM TDF only one assay was performed.
Methods and source locations

Compound reported in the paper: Tenofovir disoproxil fumarate; Compound label in the paper: TDF

Cellular prodrug activation; no direct antiviral efficacy or human exposure extrapolation.

Reagents; kinetics methods; Results: Kinetics of TDF and TFV uptake and metabolism; Figure 6 image/caption

Formation of TFV-MP and TFV-DP after TDF exposure: HPLC-MS/MS; duplicate measurements of a representative of two independent assays at 450 μM TDF; one assay at 90 μM — Figure 6A–D and Results: Kinetics of TDF and TFV uptake and metabolism

Esterase inhibition lowers cell-associated TDF-derived radioactivity

Cell-based study · VK2 cells and human PBMCs [1]

BNPP reduced cell-associated radiolabeled TDF without significantly reducing radiolabeled TFV accumulation; MTS supported absence of overt BNPP cytotoxicity under the tested conditions.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Reduction in TDF-associated cellular radioactivity in VK2Decrease versus no BNPP 52.2% ± 1.8%[1]
Reduction in TDF-associated cellular radioactivity in PBMCsDecrease versus no BNPP 35.9% ± 2.7%[1]
TFV accumulation and BNPP viability controlsControl outcomes No significant effect on TFV accumulation; no observed cytotoxicity up to 1,000 μM BNPP[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.5 μM [3H]TDF or [3H]TFV; 100 μM BNPP pretreatment
Exposure duration
BNPP pretreatment 1 h; drug exposure 1 h; viability after 2 h BNPP
Method
Liquid scintillation counting of washed cells; MTS viability assay
Co-treatment
BNPP plus labeled drug compared with no BNPP; TFV comparator tested separately
Reported limits
Vehicle not specified in selected transport subsection/caption. Cell-associated radioactivity includes parent and metabolites.
Methods and source locations

Compound reported in the paper: Tenofovir disoproxil fumarate; Compound label in the paper: TDF

Supports an esterase contribution to cellular retention; does not identify a unique causal CES isoform.

Reagents; Drug transport assays; Results: Esterase inhibition reduces TDF accumulation; Figure 5 image/caption

Reduction in TDF-associated cellular radioactivity in VK2: Means ± SEM; two independent experiments performed in duplicate; unpaired Student t test, figure *** P < 0.001 — Esterase inhibition Results; Figure 5

Reduction in TDF-associated cellular radioactivity in PBMCs: Means ± SEM; two independent experiments performed in duplicate; unpaired Student t test, figure *** P < 0.001 — Esterase inhibition Results; Figure 5

TFV accumulation and BNPP viability controls: TFV tracer and MTS controls — Esterase inhibition Results; Figure 5

Cell-type-specific IFN-λ3 induction

Cell-based study · WiDr and HT-29 colon cancer cells; negative panel spanning PBMCs, PXB hepatocytes and several non-colon cell lines [2]

TDF induced secreted IFN-λ3 in the two colon cancer cell lines, with a dose-dependent response. NUCs did not induce IFN-λ3 in the Figure 3 non-colon panel despite positive-control responsiveness.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Secreted IFN-λ3 in WiDr and HT-29Qualitative induction Increased after TDF; dose-dependent across serial dilutions[2]
IFN-λ3 in non-colon cell panelLimiting result No induction by the tested NUCs in the Figure 3 panel[2]

Literature-Reported Treatment Conditions

Treatment concentration
TDF 50 μM and serial 1:3 dilutions; comparator LAM 50 μM, ADV 2.5 μM, ETV 0.25 μM
Exposure duration
48 h
Method
In-house chemiluminescence enzyme immunoassay of supernatants
Vehicle
0.1% DMSO negative control
Co-treatment
None for selected TDF arm. IFN-α with or without poly I:C or R-837 served as positive controls, not TDF combinations.
Reported limits
Numerical dose-response parameters are not tabulated; no curve digitization. Supplementary assay details were not retrieved.
Methods and source locations

Compound reported in the paper: Tenofovir disoproxil fumarate; Compound label in the paper: TDF

Host-cell IFN-λ3 response in these models only. Downstream conditioned-medium effects used ADV and are not attributed to TDF.

Cell culture; Measurement of IFNs; Results: negative cell panel and colon-cell induction; Figures 3 and 4A–B images/captions

Secreted IFN-λ3 in WiDr and HT-29: Chemiluminescence enzyme immunoassay; Figure 4 caption reports at least three independent experiments in triplicate, representative data shown — Figure 4A–B and caption; colon cancer cell Results

IFN-λ3 in non-colon cell panel: Same 48 h assay with DMSO and positive controls — Figure 3 image/caption and preceding Results

Suppression of insulin-stimulated signaling in HepG2 cells

Cell-based study · Serum-starved HepG2 hepatoma cells [3]

TDF pretreatment reduced insulin-stimulated INSRβ phosphorylation and downstream IRS1/AKT and Gab1/SHP2 signaling relative to untreated and entecavir-treated cells.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Insulin-stimulated receptor and downstream phosphorylationQualitative immunoblot response Reduced p-INSRβ, p-IRS1/p-AKT and p-Gab1/p-SHP2 relative to NT and ETV conditions[3]

Literature-Reported Treatment Conditions

Treatment concentration
50 μM TDF; ETV and ADV comparator pretreatments also 50 μM; insulin 100 μM as reported
Exposure duration
Serum starvation 24 h; drug pretreatment 24 h; insulin 30 or 180 min
Method
Western blotting of phosphorylated and total pathway proteins
Co-treatment
Insulin stimulation after TDF pretreatment; untreated and ETV controls
Reported limits
Vehicle, biological replicate count and inferential statistics for Figure 4 blots are not specified in the selected caption.
Methods and source locations

Compound reported in the paper: Tenofovir disoproxil fumarate; Compound label in the paper: TDF

Additional host-cell signaling observation, not proof of clinical cancer prevention or an INSR enzyme IC50.

Cell culture and reagents; Western blotting; Results: Effects of NtAs on INSR signaling; Figure 4A,C,D images/caption

Insulin-stimulated receptor and downstream phosphorylation: Western blotting with total-protein and β-actin controls; no curve-derived fold change — Figure 4C–D and INSR signaling Results

Tenofovir Disoproxil Fumarate In Vivo Studies

Renal findings differed between mouse studies. Female BALB/c mice given 50–1,000 mg/kg/day TDF showed no renal histopathologic changes; 1,000 mg/kg/day caused reversible liver cytomegaly. In male C57BL/6 mice, 500–800 mg/kg/day produced renal biochemical and tubular abnormalities over four weeks. Differences in strain, sex, regimen and study design prevent a universal renal-safety conclusion; their causal contribution was not established. [4,5]

BALB/c repeat-dose toxicology and recovery

Animal study · Female BALB/c mice, 6–8 weeks; 7–15 per group at scheduled necropsies; recovery 10/group [4]

No renal histopathologic changes were found at the tested doses. The high dose caused reversible liver cytomegaly and more frequent clinical signs; all animals survived to scheduled sacrifice.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Liver cytomegaly at 1,000 mg/kg/dayHistopathologic incidence 7 of 10 after 28 days; 6 of 15 after 91 days; absent at Day 119 recovery necropsy[4]
Kidney histopathologyLimiting/negative finding No histopathologic changes in any dose group[4]
Ruffled fur and survivalClinical observations Ruffled fur: 9/35 at 50, 9/35 at 500 and 31/35 at 1,000 mg/kg; all animals survived to scheduled sacrifice[4]

Conditions shared by the study groups

Route
Oral gavage
Frequency
Once daily
Treatment course
28 or 91 days for histology; 28-day recovery subset
Vehicle
50 mM trisodium citrate dihydrate
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
50 mg/kg/day TDFMatched vehicle controlNo kidney histopathologic change; no liver cytomegaly.[4]
500 mg/kg/day TDFMatched vehicle controlNo kidney histopathologic change; no liver cytomegaly.[4]
1000 mg/kg/day TDFMatched vehicle controlNo kidney histopathologic change; minimal/mild liver cytomegaly in 7/10 after 28 days and 6/15 after 91 days, absent after 28-day recovery.[4]
50 mg/kg/day TDF
Model: Female BALB/c mice, 6–8 weeks
500 mg/kg/day TDF
Model: Female BALB/c mice, 6–8 weeks
1000 mg/kg/day TDF
Model: Female BALB/c mice, 6–8 weeks
Methods and source locations

Compound reported in the paper: Tenofovir disoproxil fumarate; Compound label in the paper: TDF

Model-specific toxicology; absence of renal lesions does not prove absence of renal toxicity in other conditions.

Animals; Study Design; Histopathology; toxicity Results; Table 1; Figure 2

Liver cytomegaly at 1,000 mg/kg/day: Veterinary histopathology; minimal/mild severity — Necropsy and Histopathology; Figure 2

Kidney histopathology: Kidney histology — Table 1; Necropsy and Histopathology

Ruffled fur and survival: Daily then weekly observations; denominators as reported, not histology sample sizes — Clinical Signs; Table 1

50 mg/kg/day TDF · Study Design; Table 1; Necropsy and Histopathology; Figure 2

500 mg/kg/day TDF · Study Design; Table 1; Necropsy and Histopathology; Figure 2

1000 mg/kg/day TDF · Study Design; Table 1; Necropsy and Histopathology; Figure 2

High-dose renal toxicity in C57BL/6 mice

Animal study · Male C57BL/6NCrljOri mice, 7 weeks; 12 assigned per group, planned 3 per weekly terminal group [5]

High-dose oral TDF produced biochemical renal impairment and renal tubular lesions. The 200 mg/kg group lacked marked BUN/creatinine changes or histologic lesions; urinary endpoints could change at lower doses.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Serum BUN and creatinineQualitative statistically significant changes 800 mg/kg/day: BUN elevated from week 1; creatinine elevated weeks 2–4 versus control; 200 mg/kg/day: no remarkable increase[5]
Renal tubular pathologyHistologic lesions Pyknotic cells: 800 mg/kg/day from week 2; 500 mg/kg/day from week 3; congestion/hemorrhage at 800 mg/kg/day in week 3[5]

Conditions shared by the study groups

Route
Oral administration
Frequency
Once daily
Treatment course
Up to four weeks; weekly terminal groups
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
200 mg/kg/day TDFVehicle-treated group G0; vehicle composition not identified in MethodsNo remarkable increase in BUN/creatinine or significant renal histologic alteration; urinary findings were more sensitive and are not taken as absence of all effects.[5]
500 mg/kg/day TDFVehicle-treated group G0; vehicle composition not identified in MethodsHigher BUN versus control; renal tubular pyknotic cells from week 3.[5]
800 mg/kg/day TDFVehicle-treated group G0; vehicle composition not identified in MethodsHigher BUN from week 1 and creatinine from weeks 2–4; pyknotic tubular cells from week 2, congestion/hemorrhage at week 3.[5]
200 mg/kg/day TDF
Model: Male C57BL/6NCrljOri mice, 7 weeks
Reported limits: Vehicle formulation not reported in selected methods.
500 mg/kg/day TDF
Model: Male C57BL/6NCrljOri mice, 7 weeks
Reported limits: Vehicle formulation not reported in selected methods.
800 mg/kg/day TDF
Model: Male C57BL/6NCrljOri mice, 7 weeks
Reported limits: Vehicle formulation not reported in selected methods.
Methods and source locations

Compound reported in the paper: Tenofovir disoproxil fumarate; Compound label in the paper: TDF

High-dose mouse toxicology only; cannot resolve strain/sex/exposure-dependent differences or predict clinical risk.

Sections 2.1–2.8; 3.1–3.4; Figures 3–4 images/captions

Serum BUN and creatinine: Blood chemistry analyzer; ANOVA with LSD comparisons, P < 0.05 as reported — Section 3.3; Figure 3 image/caption

Renal tubular pathology: H&E sections; no exact incidence inferred from representative micrographs — Section 3.4; Figure 4 image/caption

200 mg/kg/day TDF · Sections 2.2–2.4, 3.2–3.4; Figures 3–4

500 mg/kg/day TDF · Sections 2.2–2.4, 3.2–3.4; Figures 3–4

800 mg/kg/day TDF · Sections 2.2–2.4, 3.2–3.4; Figures 3–4

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 202138-50-9
Applications nucleotide reverse transcriptase inhibitor
Formula C19H30N5O10P.C4H4O4
Molecular Weight 635.51
Synonyms Viread
SMILES
C[C@H](CN1C=NC2=C1N=CN=C2N)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C.C(=C/C(=O)O)\C(=O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 88 mg/mL (138.47 mM)
Water Insoluble
Ethanol 39 mg/mL (61.36 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Tenofovir Disoproxil Fumarate Research References

  1. [1] Taneva E, Crooker K, Park SH, et al. Differential Mechanisms of Tenofovir and Tenofovir Disoproxil Fumarate Cellular Transport and Implications for Topical Preexposure Prophylaxis. Antimicrobial agents and chemotherapy (2016). PMID: 26711762 DOI: 10.1128/aac.02793-15 Source material
  2. [2] Murata K, Asano M, Matsumoto A, et al. Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection. Gut (2018). PMID: 27789659 DOI: 10.1136/gutjnl-2016-312653 Source material
  3. [3] Shimizu R, Murai K, Tanaka K, et al. Nucleos(t)ide analogs for hepatitis B virus infection differentially regulate the growth factor signaling in hepatocytes. Hepatology communications (2024). PMID: 38180972 DOI: 10.1097/hc9.0000000000000351 Source material
  4. [4] Ng HH, Stock H, Rausch L, et al. Tenofovir disoproxil fumarate: toxicity, toxicokinetics, and toxicogenomics analysis after 13 weeks of oral administration in mice. International journal of toxicology (2015). PMID: 25568137 DOI: 10.1177/1091581814565669 Source material
  5. [5] Jang E, Lee JK, Inn KS, et al. Renal Dysfunction and Tubulopathy Induced by High-Dose Tenofovir Disoproxil Fumarate in C57BL/6 Mice. Healthcare (Basel, Switzerland) (2020). PMID: 33096887 DOI: 10.3390/healthcare8040417 Source material

Publications

2 publications citing this product

  1. Ryogo Shimizu, .et al. , Hepatol Commun, 2024, Jan 5;8(1):e0351 PMID: 38180972
  2. Kazumoto Murata, .et al. , Gut, 2018, Feb; 67(2): 362-371 PMID: 27789659

Added to your cart

View Cart Checkout
Loading...